| Today’s Big NewsFeb 26, 2024 |
|
Thursday, March 7, 2024 | 1pm ET / 10am PT Join us for this timely look at the critical role a CDMO’s process development approach can play in shortening development timelines for biotherapeutics. Gain key insights on risk-mitigation strategies, utilizing flexible development platforms, optimizing integration, managing process development, and more. Register now. |
|
| By Max Bayer Johnson & Johnson is closing a nearly 200,000 square-foot R&D outpost in Brisbane, California, less than 18 months after it opened, according to multiple sources familiar with the decision. |
|
|
|
By Zoey Becker In its first six months of commercial availability, Krystal's topical gene therapy Vyjuvek raked in more than $50 million. Now, the company is looking toward bringing the drug to Europe and Japan and testing a new eye-drop formulation. |
By Andrea Park About three months after first alerting patients and healthcare providers to Nurse Assist’s voluntary recall of several of its sodium chloride irrigation and sterile water products, the FDA is now highlighting the broad reach of the recall. |
By Max Bayer While there wasn't another $3 billion private financing in 2023, it doesn't mean there wasn't plenty of money flowing. |
|
Thursday, March 7, 2024 | 2pm ET / 11am PT Join us for this discussion on the future of cloud computing in healthcare. Learn key insights on the investments being made to advance research and commercial efforts. We will explore topics such as data sharing without data movement, the future of analytics and privacy, the use of ML models for lookalike audiences supported by cloud computing, and more. Register now. 
|
|
By Fraiser Kansteiner Amgen is now open for business in Central Ohio after cutting the ribbon at its “most advanced facility to date.” Dubbed “Amgen Ohio,” the nearly 300,000-square-foot biomanufacturing plant in New Albany, Ohio, is set to employ 400 full-time employees and leverage the “latest innovation and technology." |
By Conor Hale The MIRA system is small enough to fit in a standard surgical tray, weighing only two pounds. With a camera and two robotic arms, it is designed to be placed entirely inside the patient’s abdomen and to conduct its work through a single cut in the navel. |
By Gabrielle Masson As Denali Therapeutics narrows in on large molecule biotherapeutics, the company is reorganizing, laying off an undisclosed number of workers and sending some to a new small molecule spin-out. |
By Angus Liu The chilling wind of the biotech winter has apparently spared BeiGene. While layoffs have been commonplace in the industry, BeiGene employed 1,400 more people at the beginning of 2024 than it did a year ago. |
By Conor Hale The company announced its LumiGlide system helped guide minimally invasive procedures, with a first focus on operations to repair aortic aneurysms. |
By Gabrielle Masson Novo Nordisk is getting sticky, coming together with Neomorph in a new licensing pact worth up to $1.46 billion across multiple molecular glue targets. |
By Andrea Park A new AI algorithm may be able to replace the bulky and often expensive equipment typically used to produce accurate diagnoses of sleep disorders. |
By Kevin Dunleavy For the third straight year, Sanofi CEO Paul Hudson has seen a slight dip in his compensation. For 2023, Hudson will receive 10.57 million euros ($11.44 million) in total pay, according to the company’s annual filing. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we explore the impact of environmental, social, and governance measures, commonly known as ESG, on the pharmaceutical industry. Fierce Pharma's Fraiser Kansteiner engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights and discuss Lilly's specific ESG initiatives. |
|
|---|
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
